Fig. 9From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)Probabilistic sensitivity analysis for CAZ-AVI sequence vs. meropenem sequence (on cost-effectiveness acceptability curve). Abbreviations: CAZ-AVI ceftazidime-avibactam, QALY quality-adjusted life year. CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem. Meropenem sequence: Meropenem, followed by colistin + tigecycline + high-dose meropenemBack to article page